This week we welcome Magdalena Tyrpien, CEO, Co-Founder and President of Nionyx Bio, just days after the company took first place in the BIO-Europe Spring Startup Spotlight competition in Lisbon.

With a background that includes leading Forge Biologics through its $620 million acquisition, Magdalena is now steering Nionyx toward a bold new chapter in gene therapy for kidney disease. In this episode we explore her journey into biotech, the science behind Nionyx’s proprietary AAV capsid platform and Kidney Atlas, what it took to win the Startup Spotlight, and what the victory means for the young company’s future.

·  01:25 – Meet Magdalena Tyrpien

·  07:10 – The Nionyx mission

·  15:29 – The 2026 BIO-Europe Spring Startup Spotlight

·  22:23 – Looking forward and future milestones

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

To dive deeper into the topic: 

• Lisbon is calling: the BIO-Europe Startup Spotlight returns in March 2026
• BIO-Europe Spring 2026: partnership event brings funding hope to biotechs
• BIO-Europe partnering: Australian biotech companies share their experiences